Dashboard
Manage Tickers

SGMO


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sangamo-therapeutics-to-present-neurology-focused-pre-clinical-data-from-epigenetic-regulation-capsid-delivery-and-genome-engineering-platforms-at-27th-asgct-annual-meeting
Sangamo Therapeutics To Present Neurology-...
04/22/2024 20:36:23

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
03/22/2024 17:31:17

sangamo-therapeutics-announces-pricing-of-24m-registered-direct-offering
Sangamo Therapeutics Announces Pricing Of ...
03/22/2024 12:05:53

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that it has entered into a securities pur...

analyst-bullish-on-gene-therapy-focused-voyager-therapeutics-sees-best-in-class-potential-for-its-neurogenetic-medicine-platform
Analyst Bullish On Gene Therapy-Focused Vo...
03/19/2024 18:16:11

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising...

hc-wainwright--co-reiterates-buy-on-sangamo-therapeutics-raises-price-target-to-5
HC Wainwright & Co. Reiterates Buy on Sang...
03/19/2024 10:25:40

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and raises the pri...

rbc-capital-reiterates-sector-perform-on-sangamo-therapeutics-maintains-2-price-target
RBC Capital Reiterates Sector Perform on S...
03/14/2024 15:28:26

RBC Capital analyst Luca Issi reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Sector Perform and maintains $2 price tar...

4-analysts-assess-sangamo-therapeutics-what-you-need-to-know
4 Analysts Assess Sangamo Therapeutics: Wh...
03/13/2024 18:00:25

hc-wainwright--co-maintains-buy-on-sangamo-therapeutics-maintains-3-price-target
HC Wainwright & Co. Maintains Buy on Sanga...
03/13/2024 16:48:48

HC Wainwright & Co. analyst Patrick Trucchio maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $3 pr...

sangamo-therapeutics-expects-total-operating-expenses-in-the-range-of-145m-165m-in-2024
Sangamo Therapeutics Expects Total Operati...
03/13/2024 12:16:56

Financial Guidance for 2024On a GAAP basis, we expect total operating expenses in the range of approximately $145 million to $1...

sangamo-therapeutics-q4-eps-034-misses-026-estimate-sales-204m-miss-810m-estimate
Sangamo Therapeutics Q4 EPS $(0.34) Misses...
03/13/2024 12:15:50

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate o...

sangamo-therapeutics-announces-data-from-stac-bbb-demonstrating-robust-penetration-of-the-blood-brain-barrier-bbb-and-strong-transgene-expression-throughout-the-central-nervous-system-cns-of-nhps
Sangamo Therapeutics Announces Data From S...
03/13/2024 12:06:37

earnings-scheduled-for-march-13-2024
Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
02/19/2024 17:30:50

hc-wainwright--co-reiterates-buy-on-sangamo-therapeutics-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Sang...
02/12/2024 17:48:07

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $3 p...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
02/12/2024 17:31:18

sangamo-therapeutics-announces-fda-alignment-on-abbreviated-pathway-to-potential-approval-and-ema-prime-eligibility-for-st-920-in-fabry-disease
Sangamo Therapeutics Announces FDA Alignme...
02/12/2024 13:06:17

- U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory ...

hc-wainwright--co-reiterates-buy-on-sangamo-therapeutics-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Sang...
02/06/2024 13:49:19

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $3 p...

why-palantir-technologies-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket
Why Palantir Technologies Shares Are Tradi...
02/06/2024 13:16:16

Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported bet...

sangamo-therapeutics-reports-updated-preliminary-data-from-phase-12-staar-clinical-study-evaluating-isaralgagene-civaparvovec-or-st-920-says-productive-discussions-are-continuing-with-fda-on-pathways-to-registration
Sangamo Therapeutics Reports Updated Preli...
02/05/2024 23:09:19

In the largest known clinical gene therapy program in Fabry disease to date, data from 24 patients continued to show durable sa...

sangamo-therapeutics-gets-european-medicines-agency-prime-designation-for-isaralgagene-civaparvovec-for-treatment-of-fabry-disease
Sangamo Therapeutics Gets European Medicin...
02/05/2024 19:33:02

https://www.ema.europa.eu/system/files/documents/chmp-annex/recommendations-eligibility-prime-scheme_en_0.pdf

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION